HighTower Advisors
ALLO icon

HighTower Advisors’s Allogene Therapeutics ALLO Stock Holding History

HighTower Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,441
Closed -$32.8K – 3804
2026
Q1 		$32.8K Buy
+13,441
New +$26.9K ﹤0.01% 3737
2025
Q4 		– Sell
-11,740
Closed -$14.6K – 3658
2025
Q3 		$14.6K Sell
11,740
-410
-3% -$489 ﹤0.01% 3687
2025
Q2 		$13.7K Hold
12,150
– – ﹤0.01% 3626
2025
Q1 		$17.7K Hold
12,150
– – ﹤0.01% 3525
2024
Q4 		$25.9K Sell
12,150
-17,500
-59% -$43.2K ﹤0.01% 3519
2024
Q3 		$82K Sell
29,650
-906
-3% -$2.42K ﹤0.01% 3346
2024
Q2 		$72K Hold
30,556
– – ﹤0.01% 3261
2024
Q1 		$137K Buy
30,556
+5,000
+20% +$20.9K ﹤0.01% 3079
2023
Q4 		$82K Sell
25,556
-30,303
-54% -$85.9K ﹤0.01% 3235
2023
Q3 		$176K Sell
55,859
-468
-0.8% -$2.05K ﹤0.01% 2950
2023
Q2 		$279K Sell
56,327
-532
-0.9% -$2.88K ﹤0.01% 2611
2023
Q1 		$280K Sell
56,859
-488
-0.9% -$3.13K ﹤0.01% 2507
2022
Q4 		$361K Sell
57,347
-10,712
-16% -$99.2K ﹤0.01% 2344
2022
Q3 		$734K Hold
68,059
– – ﹤0.01% 1788
2022
Q2 		$776K Buy
68,059
+17,500
+35% +$155K ﹤0.01% 1788
2022
Q1 		$462K Sell
50,559
-30
-0.1% -$312 ﹤0.01% 2223
2021
Q4 		$753K Sell
50,589
-1,220
-2% -$21.5K ﹤0.01% 1917
2021
Q3 		$1.33M Buy
51,809
+5,500
+12% +$131K ﹤0.01% 1498
2021
Q2 		$1.21M Sell
46,309
-2,000
-4% -$57K ﹤0.01% 1524
2021
Q1 		$1.7M Hold
48,309
– – 0.01% 1218
2020
Q4 		$1.22M Buy
48,309
+3,850
+9% +$125K 0.01% 1162
2020
Q3 		$1.68M Sell
44,459
-1,826
-4% -$68.8K 0.01% 954
2020
Q2 		$1.98M Sell
46,285
-10,160
-18% -$367K 0.01% 805
2020
Q1 		$1.1M Buy
+56,445
New +$1.34M 0.01% 962
2019
Q4 		– Sell
-23,140
Closed -$630K – 2310
2019
Q3 		$630K Buy
23,140
+11,738
+103% +$334K ﹤0.01% 1397
2019
Q2 		$306K Buy
+11,402
New +$318K ﹤0.01% 1792

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

HighTower Advisors's ALLO Position: Q2 2026 in Review

HighTower Advisors sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 13,441 shares — an estimated $32.8K sold.

HighTower Advisors first reported a position in ALLO in Q2 2019 and held it in 26 quarters. The position peaked at $1.98M in Q2 2020. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • HighTower Advisors reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HighTower Advisors sold 13,441 Allogene Therapeutics shares in Q2 2026, an estimated $32.8K.
  • HighTower Advisors first reported a position in Allogene Therapeutics in Q2 2019 and held it in 26 quarters.
  • HighTower Advisors's Allogene Therapeutics position peaked at $1.98M in Q2 2020.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.